Page 229 - Read Online

studies have shown that medicinal herbs and natural agents Chapelon F, Kaaks R, Lukanova A, Boeing H, Aleksandrova K,
rich in antioxidants and other safety micronutrients protect Benetou V, Zylis D, Palli D, Pala V, Panico S, Tumino R, Sacerdote
against hepatic dysfunction, carcinogenesis, mutagenesis, C, Bueno-De-Mesquita HB, Van Kranen HJ, Peeters PH, Lund E,
Quirós JR, González CA, Sanchez Perez MJ, Navarro C, Dorronsoro
DNA-damage and LPO. The greatly positive effect of natural M, Barricarte A, Lindkvist B, Regnér S, Werner M, Hallmans G, Khaw
antioxidants on membrane stabilizing by mechanisms KT, Wareham N, Key T, Romieu I, Chuang SC, Murphy N, Boffetta P,
that include up-regulation of the key apoptotic regulators, Trichopoulou A, Riboli E. Hepatocellular carcinoma risk factors and
modulate cell cycle arrest and improvement of DNA content disease burden in a European cohort: a nested case-control study. J Natl
Cancer Inst 2011;103:1686-95.
by the free radical scavenging, the antimutagenic and 16. Regimbeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand
antioxidant properties. Thus, it was recommended that the F, Nagorney DM, Ikai I, Yamaoka Y, Belghiti J. Risk factors for
supplementation with edible natural agents may help in early death due to recurrence after liver resection for hepatocellular
safe application of cancer technology in medicine as well as carcinoma: results of a multicenter study. J Surg Oncol 2004;85:36-41.
in many other aspects of nowadays life. 17. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular
carcinoma and consequences for treatment. Oncologist 2010;4:14-22.
18. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics.
Financial support and sponsorship J Hepatol 2010;52:252-7.
Nil. 19. Sohal DP, Sun W. Hepatocellular carcinoma: prevention and therapy.
Curr Oncol Rep 2011;13:186-94.
Conflicts of interest 20. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of
There are no conflicts of interest. hepatocellular carcinoma. Hepatology 2008;48:2047-63.
21. Farazi PA, Glickman J, Horner J, Depinho RA. Cooperative interactions
of p53 mutation, telomere dysfunction, and chronic liver damage in
REFERENCES hepatocellular carcinoma progression. Cancer Res 2006;66:4766-73.
22. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global HPB (Oxford) 2005;7: 26-34.
cancer statistics. CA Cancer J Clin 2011;61:69-90. 23. Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and
2. Marquardt JU, Galle PR, Teufel A. Hepatocellular carcinoma molecular lipoprotein metabolism. Lipids Health Dis 2006;5:4.
pathogenesis and novel targets for therapy. Dutch Med Wochenschr 24. Das UN, Madhavi N, Sravan Kumar G, Padma M, Sangeetha P. Can
2012;137:855-60. tumor cell drug resistance be reversed by essential fatty acids and their
3. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, metabolites? Prostaglandins Leukot Essent Fatty Acids 1998;58:39-54.
Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH; Asian 25. Tapiero H, Ba GN, Couvreur P, Tew KD. Polyunsaturated fatty acids
Oncology Summit. Management of hepatocellular carcinoma in Asia: (PUFA) and eicosanoids in human health and pathologies. Biomed
consensus statement from the Asian Oncology Summit 2009. Lancet Pharmacother 2002;56:215-22.
Oncol 2009;10:1111-8. 26. Honarmand H, Mirzajani E, Rahbar-Taromsari M, Saadat F, Mirblock
4. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. F, Mashayekhi F. The relationship and diagnostic value of C-reactive
Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. protein (CRP) and C-reactive protein (hsCRP) for myocardial
World J Gastroenterol 2008;14:4300-8. infarction. Afr J Microbiol Res 2011;5:3215-9.
5. Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, 27. Hutchinson DR, Halliwell RP, Smith MG, Parke DV. Serum
Sotorríos NG, Martínez I, Rodrigo L. Prospective analysis of risk “prealbumin” as an index of liver function in human hepatobiliary
factors for hepatocellular carcinoma in patients with liver cirrhosis. disease. Clin Chem Acta 1981;114:69-74.
Hepatol J 2003;37:520-7. 28. Ahmed KM, Saleh EM, Sayed EM, Shalaby KAF. Anti-inflammatory
6. Choi BG, Park SH, Byun JY, Jung SE, Choi KH, Han JY. The findings effect ofdifferent propolis extracts in thioacetamide-induced
of ruptured hepatocellular carcinoma on helical CT. Br J Radiol hepatotoxicity in male rat. Aust J Basic App Sci 2012;6:29.
2001;74:142-6. 29. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice
7. Kew MC. Tumors of the liver. In: Zakim D, Boyer T, editors. A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M,
Hepatology: A textbook of liver disease. 3rd ed. Philadelphia: WB Caraglia M, Sperlongano P. Molecular targets and oxidative stress
Saunders Company; 1996. p.1513. biomarkers in hepatocellular carcinoma: an overview. J Transl Med
8. Rossetto D, Truman AW, Kron SJ, Côté J. Epigenetic modifications in 2011;9:171.
double-strand break DNA damage signaling and repair. Clin Cancer 30. Hassan HA, Edrees GM, El-Gamel EM, El-Sayed EA. Amelioration of
Res 2010;16:4543-52. cisplatin-induced nephrotoxicity by grape seed proanthocynidin extract
9. Kassianides C, Kew MC. The clinical manifestations and natural and fish oil is mediated by lowering oxidative stress and DNA damage.
history of hepatocellular carcinoma. Gastroenterol Clin North Am Cytotechnology 2014;66:419-29.
1987;16:553-62. 31. Banakar MC, Paramasivan SK, Chattopadhyay MB, Datta S,
10. McGlynn KA, London WT. The global epidemiology of hepatocellular Chakraborty P. 1alpha, 25-dihydroxyvitamin D3 prevents DNA
carcinoma: present and future. Clin Liver Dis 2011;15:223-43. damage and restores antioxidant enzymes in rat hepatocarcinogenesis
11. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27. induced by diethylnitrosamine and promoted by phenobarbital. World J
12. Bruix J, Sherman M; Practice Guidelines Committee, American Gastroenterol 2004;10:1268-75.
Association for the Study of Liver Diseases. Management of 32. Revathi R, Manju V. The effects of Umbelliferone on lipid peroxidation
hepatocellular carcinoma. Hepatology 2005;42:1208-36. and antioxidant status in diethylnitrosamine induced hepatocellular
13. Besaratinia A, Kim SI, Hainaut P, Pfeifer GP. In vitro recapitulating of carcinoma. Acute J Med 2013;3:73-82.
TP53 mutagenesis in hepatocellular carcinoma associated with dietary 33. Chen B, Ning M, Yang G. Effect of paeonol on antioxidant and
aflatoxin B1 exposure. Gastroenterology 2009;137:1127-37. immune regulatory activity in hepatocellular carcinoma rats. Molecules
14. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, 2012;17:4672-83.
Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol 34. Trush MA, Kensler TW. Role of free radicals in carcinogenic activation.
and hepatocellular carcinoma: the effect of lifetime intake and hepatitis In: Sies H, editor. Oxidative Stress: Oxidants and Antioxidants. London,
virus infections in men and women. Am J Epidemiol 2002;155: 323-31. UK: Academic Press; 1991. p. 277-318.
15. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, 35. Ljubuncic P, Song H, Cogan U, Azaizeh H, Bomzon A. The effects
Pischon T, Nöthlings U, Overved K, Tjønneland A, Outzen M, Clavel- of aqueous extracts prepared from the leaves of Pastacia lentiscus in
220 Hepatoma Research | Volume 2 | August 5, 2016